Compare Moderna, Inc. (MRNA) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tidewater Inc — how do they compare? Moderna, Inc. trades at $220.65 (market cap $78.65B), while Tidewater Inc trades at $85.15 (market cap $4.21B). The key difference: Moderna, Inc. is far larger — about 18.7× Tidewater Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Tidewater Inc for 26 Days on average.
| MRNA | TDW | |
|---|---|---|
Market Cap | $78.65B | $4.21B |
Volume | 37,373,437 | 590,005 |
Sector | Health | Energy |
52-Week High | $203.46 | $100.61 |
52-Week Low | $22.36 | $47.29 |
Typical Hold Time | 59 Days | 26 Days |
Enterprise Value | $74.80B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Tidewater (TDW) trades at $85.19, up 2.15% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 earnings have missed expectations in two quarters. Recent news includes the completion of the Wilson Sons Ultratug acquisition in August 2026, and institutional interest remains strong with BlackRock's $503.2M investment.
Outlook is cautiously optimistic with a consensus price target of $105.50, but risks include earnings volatility and competitive pressures. The stock offers potential upside from operational improvements and acquisition synergies, yet investors should monitor execution on future earnings and market conditions in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
